Common Contracts
54 similar Underwriting Agreement contracts by Volcon, Inc., ParaZero Technologies Ltd., YY Group Holding Ltd., others
UNDERWRITING AGREEMENTUnderwriting Agreement • August 20th, 2024 • Impact Biomedical Inc. • Pharmaceutical preparations • New York
Impact BioMedical Inc., a corporation incorporated under the law of the State of Nevada (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Revere Securities, LLC and Dawson James Securities, Inc. (each an “Underwriter” and together, the “Underwriters”) an aggregate of 1,500,000 shares (the “Closing Shares”) of its common stock, par value $0.001 per share (the “Common Stock”). No Closing Shares will be certificated. At the option of the Underwriters, the Company agrees, subject to the terms and conditions herein, to issue and sell additional Option Shares (as defined in Section 3(b) hereof). The Closing Shares and the Option Shares are herein referred to collectively as the “Securities”. The number of Closing Shares and Option Shares to be purchased by each Underwriter is set forth opposite its name in Schedule I hereto. Each of the Underwriters has agreed to act as underwriters in connection with the offering and sale
Underwriting Agreement August 7, 2024Underwriting Agreement • August 9th, 2024 • Expion360 Inc. • Miscellaneous electrical machinery, equipment & supplies • New York
Expion360 Inc., a Nevada corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of 50,000,000 of the Company’s units (each, a “Closing Unit”), with each Closing Unit consisting of either: (A) one (1) share of Common Stock, $0.001 par value per share of the Company (the “Common Stock”) and two (2) Series A warrants (each, a “Series A Warrant”), each to purchase one (1) share of Common Stock at a per Share exercise price of $0.24 and one (1) Series B warrant (each, a “Series B Warrant” and, collectively with the Series A Warrants, the “Warrants”) to purchase such number of shares of Common Stock as determined on the Reset Date (as defined in the Series B Warrant), and in accordance with the terms therein (each, a “Closing Common Unit”); or (B) one pre-funded warrant (each, a “Pre-funded Warrant”) to purchase one (1) share of Common Stock at an exercise price o
Underwriting Agreement July [●], 2024Underwriting Agreement • July 25th, 2024 • Expion360 Inc. • Miscellaneous electrical machinery, equipment & supplies • New York
Expion360 Inc., a Nevada corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of [●] of the Company’s units (each, a “Closing Unit”), with each Closing Unit consisting of either: (A) one (1) share of Common Stock, $0.001 par value per share of the Company (the “Common Stock”) and two (2) Series A warrants (each, a “Series A Warrant”), each to purchase one (1) share of Common Stock at a per Share exercise price of $[●] and one (1) Series B warrant (each, a “Series B Warrant” and, collectively with the Series A Warrants, the “Warrants”) to purchase such number of shares of Common Stock as determined on the Reset Date (as defined in the Series B Warrant), and in accordance with the terms therein (each, a “Closing Common Unit”); or (B) one pre-funded warrant (each, a “Pre-funded Warrant”) to purchase one (1) share of Common Stock at an exercise price of $0.001
Underwriting Agreement June 27, 2024Underwriting Agreement • June 28th, 2024 • Bluejay Diagnostics, Inc. • Surgical & medical instruments & apparatus • New York
Bluejay Diagnostics, Inc., a Delaware corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of 5,368,098 of the Company’s units (each, a “Closing Unit”), with each Closing Unit consisting of either: (A) one (1) share of Common Stock, $0.0001 par value per share (the “Closing Shares”) of the Company (the “Common Stock”) and two (2) Class C warrants (each, a “Class C Warrant, each to purchase one (1) share of Common Stock at a per Share exercise price of $1.96 and one (1) Class D warrant (each, a “Class D Warrant”) to purchase such number of shares of common stock as determined on the Reset Date (as defined in the Class D Warrant), and in accordance with the terms therein (each, a “Closing Common Unit”); or (B) one pre-funded warrant (each, a “Pre-funded Warrant”) to purchase one (1) share of Common Stock at an exercise price of $0.0001 and two (2) Class C Wa
Underwriting AgreementUnderwriting Agreement • June 17th, 2024 • Bluejay Diagnostics, Inc. • Surgical & medical instruments & apparatus • New York
Underwriting AgreementUnderwriting Agreement • May 3rd, 2024 • Cemtrex Inc • Electronic components & accessories • New York
Cemtrex Inc., a Delaware corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of 11,764,705 of the Company’s units (each, a “Closing Unit”), with each Closing Unit consisting of either: (A) one (1) share of Common Stock, $0.001 par value per share (the “Closing Shares”) of the Company (the “Common Stock”) and one (1) Series A warrant (each, a “Series A Warrant”) to purchase one (1) share of Common Stock at a per Share exercise price of $0.85 and one (1) Series B warrant (each, a “Series B Warrant”) to purchase one (1) share of Common Stock at a per Share exercise price of $0.85 (each, a “Closing Common Unit”); or (B) one pre-funded warrant (each, a “Pre-funded Warrant”) to purchase one (1) share of Common Stock at an exercise price of $0.001 and one (1) Series A Warrant and one (1) Series B Warrant (each, a “Closing Pre-funded Unit”). The shares of Common
ContractUnderwriting Agreement • April 24th, 2024 • YY Group Holding Ltd. • Services-help supply services • New York
Underwriting AgreementUnderwriting Agreement • April 23rd, 2024 • Cemtrex Inc • Electronic components & accessories • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • March 8th, 2024 • Bynd Cannasoft Enterprises Inc. • Services-prepackaged software • New York
UNDERWRITING AGREEMENT February 13, 2024Underwriting Agreement • February 15th, 2024 • Sunshine Biopharma, Inc • Pharmaceutical preparations • New York
Sunshine Biopharma, Inc., a Colorado corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of 71,428,571 of the Company’s units (each, a “Closing Unit”), with each Closing Unit consisting of either: (A) one (1) share of Common Stock, $0.001 par value per share (the “Closing Shares”) of the Company (the “Common Stock”) and one-tenth (1/10th) of a Series A warrant to purchase one (1) share of Common Stock at a per Share exercise price of $2.10 (representing 1500.0% of the per Closing Common Unit (as defined below) offering price; and two-tenths (2/10th) of a Series B warrant to purchase one (1) share of Common Stock at a per Share exercise price of $2.38 (representing 1700.0% of the per Closing Common Unit (as defined below) offering price (each, a “Closing Common Unit”); or (B) one pre-funded warrant (each, a “Pre-funded Warrant”) to purchase one (1) share o
UNDERWRITING AGREEMENTUnderwriting Agreement • February 9th, 2024 • Sunshine Biopharma, Inc • Pharmaceutical preparations • New York
ContractUnderwriting Agreement • December 8th, 2023 • YY Group Holding Ltd. • Services-help supply services • New York
TUNGRAY TECHNOLOGIES INC [●] Class A Ordinary Shares FORM OF UNDERWRITING AGREEMENTUnderwriting Agreement • November 29th, 2023 • Tungray Technologies Inc • Construction, mining & materials handling machinery & equip • New York
Underwriting AgreementUnderwriting Agreement • November 20th, 2023 • Volcon, Inc. • Motor vehicles & passenger car bodies • New York
Volcon, Inc., a Delaware corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) (i) an aggregate of 42,857,142 common units (“Common Units”), each consisting of one share of common stock (the “Firm Shares”), par value $0.00001 per share, of the Company (the “Common Stock”), 0.35 of a series A warrant to purchase one share of Common Stock (“Series A Warrants”) and 0.35 of a series B warrant (“Series B Warrants”) to purchase one share of Common Stock (collectively, the “Warrants”) and/or (ii) an aggregate of 42,857,142 pre-funded units (“Pre-funded Units”) consisting of one pre-funded warrant to purchase one share of Common Stock (the “Pre-funded Warrants”), 0.35 of a Series A Warrant and 0.35 of a Series B Warrant. The Common Units and Pre-funded Units to be sold by the Company to the Underwriter are called the “Firm Securities.” At the option of the Underwriter, the Comp
ContractUnderwriting Agreement • November 13th, 2023 • YY Group Holding Ltd. • Services-help supply services • New York
Underwriting AgreementUnderwriting Agreement • November 8th, 2023 • Volcon, Inc. • Motor vehicles & passenger car bodies • New York
Volcon, Inc., a Delaware corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) (i) an aggregate of [•] common units (“Common Units”), each consisting of one share of common stock (the “Firm Shares”), par value $0.00001 per share, of the Company (the “Common Stock”), 0.35 of a series A warrant to purchase one share of Common Stock (“Series A Warrants”) and 0.35 of a series B warrant (“Series B Warrants”) to purchase one share of Common Stock (collectively, the “Warrants”) and/or (ii) an aggregate of [•] pre-funded units (“Pre-funded Units”) consisting of one pre-funded warrant to purchase one share of Common Stock (the “Pre-funded Warrants”), 0.35 of a Series A Warrant and 0.35 of a Series B Warrant. The Common Units and Pre-funded Units to be sold by the Company to the Underwriter are called the “Firm Securities.” At the option of the Underwriter, the Company agrees, su
Underwriting AgreementUnderwriting Agreement • September 18th, 2023 • Volcon, Inc. • Motor vehicles & passenger car bodies • New York
Volcon, Inc., a Delaware corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of 1,400,000 shares of common stock (the “Firm Shares”), par value $0.00001 per share, of the Company (the “Common Stock”). The Firm Shares to be sold by the Company to the Underwriter are called the “Firm Securities”. At the option of the Underwriter, the Company agrees, subject to the terms and conditions herein, to issue and sell up to an aggregate of 210,000 additional shares of Common Stock representing fifteen percent (15.0%) of the Firm Securities sold in the offering (the “Option Securities”). The Firm Securities and the Option Securities are herein referred to collectively as the “Offered Securities”. The number of Offered Securities to be purchased by the Underwriter is set forth opposite its name in Schedule I hereto.
UNDERWRITING AGREEMENTUnderwriting Agreement • July 24th, 2023 • BioNexus Gene Lab Corp • Services-medical laboratories • New York
Underwriting AgreementUnderwriting Agreement • May 25th, 2023 • Volcon, Inc. • Motor vehicles & passenger car bodies • New York
Volcon, Inc., a Delaware corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of 6,000,000 shares of common stock (the “Firm Shares”), par value $0.00001 per share, of the Company (the “Common Stock”) and pre-funded warrants to purchase shares of Common Stock (the “Pre-funded Warrants”). The Firm Shares and Pre-funded Warrants to be sold by the Company to the Underwriter are called the “Firm Securities”. At the option of the Underwriter, the Company agrees, subject to the terms and conditions herein, to issue and sell up to an aggregate of 900,000 additional shares of Common Stock and/or Pre-funded Warrants representing fifteen percent (15.0%) of the Firm Securities sold in the offering (the “Option Securities”). The Firm Securities and the Option Securities are herein referred to collectively as the “Offered Securities”. The number of Offered Securities t
SHARES ELATE GROUP, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • April 25th, 2023 • Elate Group, Inc. • Trucking & courier services (no air) • New York
The undersigned, Elate Group, Inc., a Delaware corporation (together with its Subsidiary, the “Company”), hereby confirms its agreement (this “Agreement”) with Aegis Capital Corp. (the “Underwriter”) on the terms and conditions set forth herein. The offering and sale of the Securities contemplated by this Agreement is referred to herein as the “Offering”.
Underwriting AgreementUnderwriting Agreement • April 20th, 2023 • BioLife4D Corp • Biological products, (no disgnostic substances) • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • April 5th, 2023 • HiTek Global Inc. • Services-prepackaged software • New York
AgiiPlus Inc. [●] Class A Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • March 30th, 2023 • AgiiPlus Inc. • Real estate • New York
Harden Technologies Inc. Ordinary Shares of Par Value US$0.001 Per Share UNDERWRITING AGREEMENTUnderwriting Agreement • March 6th, 2023 • Harden Technologies Inc. • Special industry machinery, nec • New York
Underwriting AgreementUnderwriting Agreement • February 15th, 2023 • ParaZero Technologies Ltd. • Aircraft parts & auxiliary equipment, nec • New York
ParaZero Technologies Ltd., an Israeli company (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of [●] units (each, a “Closing Unit”), with each Closing Unit consisting of either: (A) one ordinary share, par value NIS 0.02 per share, of the Company (the “Ordinary Shares”) and two (2) warrants, each to purchase one Ordinary Share, at an exercise price of $[●] (equal to the price per Ordinary Share included in the Closing Common Unit (as defined below) offering price (the “Public Offering Price”) per whole share (the “Warrant”) (each, a “Closing Common Unit”); or (B) one pre-funded warrant (each, a “Pre-funded Warrant”) to purchase one Ordinary Share at an exercise price of $0.001 until such time as the Pre-funded Warrant is exercised in full subject to adjustment as provided in the Pre-funded Warrant and two Warrants (each, a “Closing Pre-funded Unit”). The Ordinar
Harden Technologies Inc. Ordinary Shares of Par Value US$0.001 Per Share UNDERWRITING AGREEMENTUnderwriting Agreement • February 14th, 2023 • Harden Technologies Inc. • Special industry machinery, nec • New York
Underwriting AgreementUnderwriting Agreement • February 9th, 2023 • Innovation Beverage Group LTD • Beverages • New York
Innovation Beverage Group Limited, an Australian corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp., (the “Underwriter”) an aggregate of [●] units (each, a “Closing Unit”), with each Closing Unit consisting one ordinary share (the “Firm Shares”), no par value per share, of the Company (the “Ordinary Shares”) and one warrant to purchase one Ordinary Share at an exercise price of $[●] (representing 100% of the per Closing Unit Public Offering Price (ad defined herein) per whole share (the “Warrant”). The Ordinary Shares referred to in this Section are hereinafter referred to as the “Closing Shares” and the Warrants referred to in this Section are hereinafter referred to as the “Closing Warrants”. No Closing Units will be certificated, and the Closing Shares and the Closing Warrants comprising the Closing Units will be separated immediately upon issuance. At the option of the Underwriter,
Underwriting AgreementUnderwriting Agreement • November 7th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • New York
Underwriting AgreementUnderwriting Agreement • November 4th, 2022 • ParaZero Technologies Ltd. • Aircraft parts & auxiliary equipment, nec • New York
ParaZero Technologies Ltd., an Israeli company (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of [●] units (each, a “Closing Unit”), with each Closing Unit consisting of either: (A) one ordinary share, par value NIS 0.02 per share, of the Company (the “Ordinary Shares”) and two (2) warrants, each to purchase one Ordinary Share, at an exercise price of $[●] (equal to the price per Ordinary Share included in the Closing Common Unit (as defined below) offering price (the “Public Offering Price”) per whole share (the “Warrant”) (each, a “Closing Common Unit”); or (B) one pre-funded warrant (each, a “Pre-funded Warrant”) to purchase one Ordinary Share at an exercise price of $0.001 until such time as the Pre-funded Warrant is exercised in full subject to adjustment as provided in the Pre-funded Warrant and two Warrants (each, a “Closing Pre-funded Unit”). The Ordinar
UNITS ELATE GROUP, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • November 1st, 2022 • Elate Group, Inc. • Trucking & courier services (no air) • New York
The undersigned, Elate Group, Inc., a Delaware corporation (together with its Subsidiary, the “Company”), hereby confirms its agreement (this “Agreement”) with Aegis Capital Corp. (the “Underwriter”) on the terms and conditions set forth herein. The offering and sale of the Securities contemplated by this Agreement is referred to herein as the “Offering”.
Underwriting AgreementUnderwriting Agreement • October 5th, 2022 • Avenue Therapeutics, Inc. • Pharmaceutical preparations • New York
Underwriting AgreementUnderwriting Agreement • September 21st, 2022 • BioLife4D Corp • Biological products, (no disgnostic substances) • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • September 16th, 2022 • HiTek Global Inc. • Services-prepackaged software • New York
The undersigned, Tianyu Xia, hereby certifies that he is the duly elected, qualified, and acting Chief Financial Officer, of Hitek Global Inc., a Cayman Islands exempted company (the “Company”), and that as such he is authorized to execute and deliver this certificate in the name and on behalf of the Company. Pursuant to Section 7(g) of the Underwriting Agreement, dated as of August [. ] , 2022 by R. F. Lafferty & Co., Inc. and Pacific Century Securities, LLC, as representatives of the underwriters listed on Schedule A thereto (the “Underwriting Agreement”), the undersigned further certifies, solely in the capacity as an officer of the Company for and on behalf of the Company as set forth below.
UNDERWRITING AGREEMENTUnderwriting Agreement • September 9th, 2022 • Infinite Group Inc • Services-prepackaged software • New York
Underwriting AgreementUnderwriting Agreement • September 7th, 2022 • ParaZero Technologies Ltd. • Aircraft parts & auxiliary equipment, nec • New York
ParaZero Technologies Ltd., an Israeli company (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. an aggregate of [●] units (each, a “Closing Unit”), with each Closing Unit consisting of either: (A) one ordinary share, par value NIS 0.02 per share, of the Company (the “Ordinary Shares”) and two (2) warrants, each to purchase one Ordinary Share, at an exercise price of $[●] (equal to the price per Ordinary Share included in the Closing Common Unit (as defined below) offering price (the “Public Offering Price”) per whole share (the “Warrant”) (each, a “Closing Common Unit”); or (B) one pre-funded warrant (each, a “Pre-funded Warrant”) to purchase one Ordinary Share at an exercise price of $0.001 until such time as the Pre-funded Warrant is exercised in full subject to adjustment as provided in the Pre-funded Warrant and two Warrants (each, a “Closing Pre-funded Unit”). The Ordinary Shares referred to
